Provided by Tiger Trade Technology Pte. Ltd.

JPMORGAN HEALTHCARE LEADERS ETF

60.56
+0.84231.41%
Post-market: 60.590.0350+0.06%16:00 EDT
Volume:34
Turnover:2K
Market Cap:9.08M
PE:- -
High:60.56
Open:59.89
Low:60.56
Close:59.71
52wk High:64.69
52wk Low:53.59
Shares:150.00K
Float Shares:150.00K
Volume Ratio:0.64
T/O Rate:0.02%
Dividend:0.51
Dividend Rate:0.84%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says

MT Newswires Live
·
Oct 06

General Medicine - Series B Financing Led by Andreessen Horowitz (a16z), with Participation from Matrix, Vxi Capital, Eli Lilly and Company

THOMSON REUTERS
·
Oct 06

Lexaria Targets Booming Oral GLP-1 Market as Industry Shifts from Injectables

TIPRANKS
·
Oct 06

European Shares Gain as Genmab Jumps, Bond Yields Retreat

Reuters
·
Oct 06

LIVE Markets-a Health Boost for the STOXX

Reuters
·
Oct 06

Genmab at 3-Year High After Blood Cancer Drug Combination Study Results

Reuters
·
Oct 06

Tech Coast Angels Reports Profitable Atraverse Medical Exit After Johnson & Johnson Acquisition, Citing 70%+ IRR

Reuters
·
Oct 06

L'Oreal Explores Unloading Chemical-Related Liabilities, WSJ Reports

Reuters
·
Oct 06

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Oct 06

AbbVie Cuts Q3 Adjusted Diluted EPS Outlook to $3.73-$3.77 After $216 Million Acquired Ipr&d, Milestones Expense

Reuters
·
Oct 06

Abbvie - Full-Year 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $13.76-$13.96 - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Gaap and Adj Earnings Include $216 Mln Bought Ipr&D and Milestones Expense - SEC Filing

THOMSON REUTERS
·
Oct 06

Abbvie Inc. Fy2026 Shr View $14.02

THOMSON REUTERS
·
Oct 06

Abbvie - Q3 2026 Adj Diluted EPS Guidance Range Including Bought Ipr&D is $3.73-$3.77 - SEC Filing

THOMSON REUTERS
·
Oct 06

Genmab, AbbVie Say New Drug Combo Helps Lymphoma Patients Stay Cancer-Free Longer

MT Newswires Live
·
Oct 06

Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL

TIPRANKS
·
Oct 06

AbbVie Blood Cancer Drug Combo Cuts Risk of Progression or Death in Late-Stage Study

Reuters
·
Oct 06

Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study

TIPRANKS
·
Oct 06

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Reuters
·
Oct 06